Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TT-00420 combined with darolutamide or enzalutamide in previously treated metastatic castration-resistant prostate cancer
ChiCTR2600132295Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tinengotinib in metastatic castration-resistant prostate cancer (mCRPC) (7 cohorts), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Dose-limiting toxicity, Incidence, duration, and severity of adverse events and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tinengotinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600132295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132295.